• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The hunt for an HIV vaccine

The hunt for an HIV vaccine

August 1, 2016
CenterWatch Staff

In the 1980s, HIV was a death sentence. Today, three decades later, clinical research has produced therapeutic breakthroughs that have turned HIV into a chronic yet manageable disease. Drugs that approach the disease from different angles, in combination with each other, are able to reduce viral load—the amount of virus in the body—to levels that are undetectable.

These drugs not only protect an individual infected with the virus from getting AIDS, they significantly limit the ability of the disease to spread from one person to another.
HIV is big business for drug makers like Gilead and ViiV who dominate the marketplace with established brands like Truvada, Atripla and Stribild, and newcomers like Triumeq and Genvoya, each one either currently making or forecast to generate $3 billion or more in sales every year.

cww2030_20160801_XuZLaZ-6

Even with all the scientific advances, clinical research has yet to find the Holy Grail: an HIV vaccine. It isn’t for lack of trying. There are 117 clinical and preclinical studies currently looking for the answer.

In the historical context, 30 years may not seem like a lot of time. It took over 100 years to find a vaccine for typhoid, 80 years for pertussis and 47 years for polio. But as science progresses, lag time between virus identification and vaccine discovery has been getting shorter. It only took 16 years to develop a vaccine for the hepatitis B virus, for example.

Since the discovery of the human immunodeficiency virus, a number of clinical trials have held promise, but ultimately failed to achieve their mission. In 2007, Merck’s highly anticipated STEP trial was terminated, marking a major setback not just for the sponsor but for vaccine development in general. The trial failed to protect against infection and failed to raise T-cell levels, negating the premise that stimulation of T-cells was the answer.

Should we be concerned that vaccine development for HIV, which has been ongoing since the 80s, has yet to yield a viable vaccine candidate?

Maybe not. The scientific challenge is an unusually difficult one, requiring researchers to develop a vaccine against a retrovirus the likes of which they’ve never seen before.

HIV is particularly adept at hiding itself from the body’s natural surveillance, allowing it to mutate and replicate quickly. Because the human immune system has a hard time detecting the presence of HIV, it can’t keep up with it. A successful vaccine would only have a small window of time—less than 24 hours—in which it could search and destroy HIV in order to be effective.

In 2009, investigators in what was known as the Thai Trial (named for its central site in Thailand) were able to trigger an immune response in people infective with HIV. Though the outcomes were not significant enough for the drug to be used as a vaccine, it was the first and only successful proof-of-concept that a vaccine could reduce transmission rates. Building on the Thai study, a new trial, known as the Uhambo Study, is now underway in South Africa using the same product, but with an effort made to make the vaccine remain active in the body for a longer period of time.

While it is possible that the trial will not yield a comprehensive vaccine, scientists believe any degree of protection could still be important in prevention when combined with antiretroviral drugs and other interventions, like medical male circumcision. The Uhambo Study will take 10 years to complete, with initial results expected for publication by 2019.

About six years ago, scientists discovered something interesting in the blood of a so-called “long-term nonprogressor”—a person who had HIV and whose body controlled the infection for more than 15 years without medicine. As it turns out, in roughly 15% of people infected with HIV, the immune system learns over time to make antibodies that fight a broad array of HIV strains.

This year a new clinical research effort is underway to explore the effectiveness of these broadly neutralizing antibodies. Whereas the Thai Trail focused on non-neutralizing antibodies, this new approach involves testing a manufactured version of a natural antibody delivered directly into the patient’s bloodstream via an intravenous infusion.

Considered a landmark clinical trial, the AMP Trial is one of two parallel studies that will span three continents and involve more than 4,000 participants—2,700 men and transgender people who have sex with men at 24 sites in the U.S., Brazil and Peru, and 1,500 sexually active women at 15 sites in Botswana, Kenya, Malawi, Mozambique, South Africa, Tanzania and Zimbabwe.

The study promises a whole set of scientific breakthroughs that could advance the science needed to make a potent HIV vaccine, and open a second avenue to pursue in the quest for a vaccine.  

Matthew Howes is executive vice president, Strategy & Growth for PALIO, an inVentiv Health company. A leader in digital strategy, he has provided the fuel for digital businesses visited by over 100 million people every month. Email matthew.howes@inventivhealth.com.

This article was reprinted from CWWeekly, a leading clinical research industry newsletter providing expanded analysis on breaking news, study leads, trial results and more. Subscribe »

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing